A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Innovent completes first patient dosing in seventh phase 3 trial (GLORY-OSA) of mazdutide in China with moderate-to-severe OSA & obesity: San Francisco, US Tuesday, June 17, 2025, ...

Deep Apple is the latest biotech to be tapped by Novo Nordisk as the drugmaker aims to regain market share lost to Eli Lilly.

Discover a recent study where the authors propose a strategic push to double the diagnostic rate of at-risk MASH by 2030.

Other drugs, including Novo Nordisk's GLP-1 agonist semaglutide, are also in late-stage development for the disease. "Testing new MASH treatments often relies on liver biopsies, where small pieces ...

Learn how SGLT2 inhibitor dapagliflozin improves MASH outcomes, with potential clinical use beyond diabetes care.

In that light, the GLP-1 rebound effect is not an obstacle but an opportunity to chart a new, holistic course in obesity care ...

Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...